{"nctId":"NCT00393523","briefTitle":"Hepatitis B Vaccine Booster Study (V232-058)(COMPLETED)","startDateStruct":{"date":"2006-09"},"conditions":["Hepatitis B"],"count":1478,"armGroups":[{"label":"5 µg Modified Process Hepatitis B Vaccine Booster (Group 1)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Modified Process Hepatitis B Vaccine"]},{"label":"10 µg ENGERIX-B™ Booster (Group 2)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Comparator: ENGERIX-B"]},{"label":"5 µg Modified Process Hepatitis B Vaccine Booster (Group 3)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Modified Process Hepatitis B Vaccine"]},{"label":"10 µg ENGERIX-B™ Booster (Group 4)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Comparator: Comparator: ENGERIX-B"]},{"label":"5 µg Modified Process Hepatitis B Vaccine (Group 5)","type":"EXPERIMENTAL","interventionNames":["Biological: Comparator: Modified Process Hepatitis B Vaccine"]}],"interventions":[{"name":"Comparator: Modified Process Hepatitis B Vaccine","otherNames":[]},{"name":"Comparator: Comparator: ENGERIX-B","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy Children 4 to 8 years of age\n* Complete medical records documenting receiving a previous hepatitis B vaccination during the first year of life (for Cohort A and B only)\n* Complete 3-dose vaccination with either a primary series of RECOMBIVAX HB or a primary series of ENGERIX-B (for Cohort A and B only)\n\nExclusion Criteria:\n\n* Birth mother known to be a carrier of hepatitis B virus (Cohort C only)\n* History of previous hepatitis B vaccine\n* History of vaccination with any hepatitis B vaccine (Cohort C only)\n* Known of suspected hypersensitivity to any component of RECOMBIVAX HB or ENGERIX-B (eg aluminum, yeast) recent administration of hepatitis B immune globulin (HBIg), serum immune globulin, or any other blood-derived product\n* Receipt of investigational drugs or vaccines within 3 months prior to study vaccine or planned within study period\n* Impairment of immunologic function or recent use of immunomodulatory medications\n* A Combination of different hepatitis B vaccines used in the primary vaccination series (Cohort A and B only)","healthyVolunteers":true,"sex":"ALL","minimumAge":"4 Years","maximumAge":"8 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy","description":"Number of subjects who received a 3-dose primary series of RECOMBIVAX HB™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"323","spread":null},{"groupId":"OG001","value":"305","spread":null}]}]}]},{"type":"SECONDARY","title":"Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy","description":"Number of subjects who received a 3-dose primary series of ENGERIX-B ™ in infancy and who demonstrated antibodies to hepatitis B surface antigen ≥10 mIU/mL at 4 weeks after receiving a booster dose of modified process hepatitis B vaccine or ENGERIX-B™.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"329","spread":null},{"groupId":"OG001","value":"313","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of RECOMBIVAX HB in Infancy","description":"Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of RECOMBIVAX HB™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"476.9","spread":null},{"groupId":"OG001","value":"561.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Antibody Response to Hepatitis B Surface Antigen in Subjects Who Received a 3-dose Primary Series of ENGERIX-B in Infancy","description":"Geometric Mean Titer (GMT) for all subjects who completed a 3-dose primary vaccination series of ENGERIX-B™ and who received a booster dose of either modified process hepatitis B vaccine or ENGERIX-B™","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1424.0","spread":null},{"groupId":"OG001","value":"1216.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":369},"commonTop":["Pain, Injection site for hepatitis B vaccine","Swelling, Injection site for hepatitis B vaccine","Erythema, Injection site for hepatitis B vaccine","Pyrexia","Headache"]}}}